Chicago Center on Musculoskeletal Pain P30

本提案是对家长资助P30 AR 079206“芝加哥肌肉骨骼疼痛中心”的补充 （C-COMP）”（2021-2026），旨在建立一个基于资源的中心，以促进和支持研究， 培训旨在了解与肌肉骨骼（MSK）相关的疼痛机制， 风湿性疾病，最终目标是更好地管理和预防它。 C-COMP的目标是：（1）促进高质量，创新，标准化，集中研究疼痛的主题， 风湿性和MSK疾病;（2）促进与预防相关的跨学科研究，基于 MSK研究人员和疼痛研究人员/神经科学家之间的合作;和（3）扩大研究 社区在这一领域，并增加校外资助这一不足的主题。 为创新和有价值的提案提供试点资金是C-COMP丰富的一个关键要素 该计划通过推进肌肉骨骼疼痛领域的高质量研究， 以及扩大研究领域。本补充材料直接针对NOSI目标B：“扩大 风湿性、皮肤和肌肉骨骼疾病疼痛研究能力（队列、技术或数据） 目前的研究基地/合作者”，寻求扩大下一个试点赠款的发放数量， 周期从4到6个奖项，每个2.5万美元。成功的试点赠款将间接促进目标A：“产生 为风湿性关节炎疼痛研究的未来创新研究或新的科学方向提供证据， 皮肤和肌肉骨骼疾病”。 我们建议将试点资金增加5万美元，这样我们就可以再发放两笔赠款，总共6笔 第二周期的奖励。两个周期的所有试点补助金获得者将被邀请到芝加哥参加第一个C- COMP年度研讨会将于2023年12月4日举行。 我们预计这种方法将增加C-COMP的覆盖面和有效性，并产生长期的 对风湿性和肌肉骨骼疾病相关疼痛研究的有益影响。

This proposal is a supplement to Parent Grant P30AR079206, “Chicago Center on Musculoskeletal Pain (C-COMP)” (2021-2026), which aims to establish a resource-based center to foster and support research and training aimed at understanding the mechanisms underlying pain associated with musculoskeletal (MSK) and rheumatic diseases, with the ultimate goal of better managing and preventing it. The long-term broad objectives of C-COMP are: (1) To foster high-quality, innovative, standardized, focused research on the topic of pain in rheumatic and MSK diseases; (2) To promote translationally relevant cross-disciplinary research, based on collaborations between MSK researchers and pain researchers/neuroscientists; and (3) To expand the Research Community in this area, and increase extramural funding for this understudied topic. Pilot funding for innovative and meritorious proposals is a key element of C-COMP’s Enrichment Program’s role in driving the field forward by advancing high quality research in the area of musculoskeletal pain, as well as expanding the field of research. This supplement directly addresses the NOSI Goal B: “Expand rheumatic, skin, and musculoskeletal disease pain research capacity (cohorts, technologies or data) beyond current research base/collaborators”, by seeking to expand the number of pilot grants to be awarded in the next cycle from 4 to 6 awards of $25K each. Indirectly, successful pilot grants will contribute to Goal A: “Generate supporting evidence towards a future innovative study or new scientific direction in pain research in rheumatic, skin, and musculoskeletal diseases”. We propose to expand the pilot funding by $50K, so that we can award two more grants – for a total of 6 awards in cycle 2. All pilot grant awardees from both cycles will be invited to Chicago to participate in the first C- COMP Annual Symposium on December 4 2023. We anticipate this approach will increase the reach and effectiveness of C-COMP and produce a longterm beneficial impact on research into pain associated with rheumatic and musculoskeletal diseases.